SCHEMBL15701190

SCHEMBL15701190

NNCCOCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.56
SMN1; SMN2 Q16637 3/20 0.54
IDO1 P14902 3/20 0.54
LMNA P02545 3/20 0.54
CYP3A4 P08684 3/20 0.54
ALDH1A1 P00352 2/20 0.54
NPC1 O15118 1/20 0.54
KDM1A O60341 1/20 0.54
CYP1A2 P05177 1/20 0.54
HTR1A P08908 1/20 0.54
ADRA2A P08913 1/20 0.54
CYP2C8 P10632 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
NFKB1 P19838 1/20 0.54
MAOA P21397 1/20 0.54
PTGS1 P23219 1/20 0.54
SLC6A2 P23975 1/20 0.54
MAOB P27338 1/20 0.54
CYP2C19 P33261 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11129793 0.98 TSHR (0.54) TSHRSMN1; SMN2IDO1LMNACYP3A4
SCHEMBL11129540 0.88 TSHR (0.52) TSHRSMN1; SMN2IDO1LMNACYP3A4
SCHEMBL13401110 0.86 TSHR (0.50) TSHRSMN1; SMN2IDO1LMNACYP3A4
Hydrochloric Acid SCHEMBL3489737 0.85 TSHR (0.48) TSHRSMN1; SMN2IDO1LMNACYP3A4
SCHEMBL8760726 0.83 TSHR (0.61) TSHRSMN1; SMN2LMNAHTR1AADRA1A
SCHEMBL7134228 0.81 TSHR (0.58) TSHRSMN1; SMN2LMNAHTR1AADRA1A
SCHEMBL25822271 0.81 ADRA1D (0.49) TSHRHTR1AMAOBADRA1AGAA
Benzene SCHEMBL9422359 0.79 TSHR (0.42) TSHRSMN1; SMN2IDO1LMNACYP3A4
SCHEMBL10810933 0.79 DRD4 (0.50) IDO1LMNACYP3A4HTR1AMAOA
SCHEMBL1991359 0.79 TSHR (0.78) TSHRSMN1; SMN2IDO1HTTAGXT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720071-A1 COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE Beone Medicines I GmbH (CH) 2026-04-08 EP disclosed
US-20240425523-A1 Compounds for the Degradation of EGFR Kinase BEONE MEDICINES I GMBH (CH) 2024-12-26 US disclosed
WO-2024246838-A1 COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE BEIGENE SWITZERLAND GMBH (CH) 2024-12-05 WO disclosed
EP-2727920-A1 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF FUJIFILM Corporation (JP) 2014-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425523-A1 Compounds for the Degradation of EGFR Kinase EGFR, ERBB2, ERBB3 TSHR 1998/4885SMN1; SMN2 4592/4885IDO1 2813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.